{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T13:24:46Z","timestamp":1785936286063,"version":"3.56.0"},"publisher-location":"Singapore","reference-count":218,"publisher":"Springer Singapore","isbn-type":[{"value":"9789811602665","type":"print"},{"value":"9789811602672","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-981-16-0267-2_1","type":"book-chapter","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T20:02:36Z","timestamp":1626206556000},"page":"1-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Antiviral Drugs Against Herpesviruses"],"prefix":"10.1007","author":[{"given":"Jocelyne","family":"Piret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"1_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/b135974_22","volume-title":"Viral genome replication","author":"G Andrei","year":"2009","unstructured":"Andrei G, Clercq E, Snoeck R (2009) Viral DNA polymerase inhibitors. In: Cameron CE, Gotte M, Raney K (eds) Viral genome replication. Springer, New York, pp 481\u2013526"},{"key":"1_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0378-1119(87)90039-4","volume":"52","author":"T Tsurumi","year":"1987","unstructured":"Tsurumi T, Maeno K, Nishiyama Y (1987) Nucleotide sequence of the DNA polymerase gene of herpes simplex virus type 2 and comparison with the type 1 counterpart. Gene 52:129\u2013137","journal-title":"Gene"},{"key":"1_CR3","doi-asserted-by":"publisher","first-page":"28059","DOI":"10.1074\/jbc.274.40.28059","volume":"274","author":"IR Lehman","year":"1999","unstructured":"Lehman IR, Boehmer PE (1999) Replication of herpes simplex virus DNA. J Biol Chem 274:28059\u201328062","journal-title":"J Biol Chem"},{"key":"1_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1432-1033.1979.tb13181.x","volume":"98","author":"KW Knopf","year":"1979","unstructured":"Knopf KW (1979) Properties of herpes simplex virus DNA polymerase and characterization of its associated exonuclease activity. Eur J Biochem 98:231\u2013244","journal-title":"Eur J Biochem"},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"19266","DOI":"10.1016\/S0021-9258(19)47296-7","volume":"264","author":"JJ Crute","year":"1989","unstructured":"Crute JJ, Lehman IR (1989) Herpes simplex-1 DNA polymerase. Identification of an intrinsic 5'-3' exonuclease with ribonuclease H activity. J Biol Chem 264:19266\u201319270","journal-title":"J Biol Chem"},{"key":"1_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.virusres.2017.01.019","volume":"234","author":"K Zarrouk","year":"2017","unstructured":"Zarrouk K, Piret J, Boivin G (2017) Herpesvirus DNA polymerases: structures, functions and inhibitors. Virus Res 234:177\u2013192","journal-title":"Virus Res"},{"key":"1_CR7","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/313762a0","volume":"313","author":"DL Ollis","year":"1985","unstructured":"Ollis DL, Brick P, Hamlin R, Xuong NG, Steitz TA (1985) Structure of large fragment of Escherichia coli DNA polymerase I complexed with dTMP. Nature 313:762\u2013766","journal-title":"Nature"},{"key":"1_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S0092-8674(00)80296-2","volume":"89","author":"J Wang","year":"1997","unstructured":"Wang J, Sattar AK, Wang CC, Karam JD, Konigsberg WH, Steitz TA (1997) Crystal structure of a pol alpha family replication DNA polymerase from bacteriophage RB69. Cell 89:1087\u20131099","journal-title":"Cell"},{"key":"1_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0092-8674(00)81647-5","volume":"99","author":"Y Shamoo","year":"1999","unstructured":"Shamoo Y, Steitz TA (1999) Building a replisome from interacting pieces: sliding clamp complexed to a peptide from DNA polymerase and a polymerase editing complex. Cell 99:155\u2013166","journal-title":"Cell"},{"key":"1_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0092-8674(01)00367-1","volume":"105","author":"MC Franklin","year":"2001","unstructured":"Franklin MC, Wang J, Steitz TA (2001) Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 105:657\u2013667","journal-title":"Cell"},{"key":"1_CR11","doi-asserted-by":"publisher","first-page":"7204","DOI":"10.1016\/S0021-9258(20)79686-9","volume":"255","author":"WH Miller","year":"1980","unstructured":"Miller WH, Miller RL (1980) Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J Biol Chem 255:7204\u20137207","journal-title":"J Biol Chem"},{"key":"1_CR12","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1016\/0006-2952(82)90305-7","volume":"31","author":"WH Miller","year":"1982","unstructured":"Miller WH, Miller RL (1982) Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 31:3879\u20133884","journal-title":"Biochem Pharmacol"},{"key":"1_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jmv.1890410503","volume":"1","author":"GB Elion","year":"1993","unstructured":"Elion GB (1993) Acyclovir: discovery, mechanism of action, and selectivity. J Med Virol Suppl 1:2\u20136","journal-title":"J Med Virol Suppl"},{"key":"1_CR14","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1016\/S0021-9258(18)83248-3","volume":"264","author":"JE Reardon","year":"1989","unstructured":"Reardon JE, Spector T (1989) Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 264:7405\u20137411","journal-title":"J Biol Chem"},{"key":"1_CR15","doi-asserted-by":"publisher","first-page":"11447","DOI":"10.1016\/S0021-9258(19)68420-6","volume":"256","author":"D Derse","year":"1981","unstructured":"Derse D, Cheng YC, Furman PA, St Clair MH, Elion GB (1981) Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function. J Biol Chem 256:11447\u201311451","journal-title":"J Biol Chem"},{"key":"1_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00003495-199447010-00009","volume":"47","author":"AJ Wagstaff","year":"1994","unstructured":"Wagstaff AJ, Faulds D, Goa KL (1994) Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:153\u2013205","journal-title":"Drugs"},{"issue":"Suppl 1","key":"1_CR17","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1086\/342966","volume":"186","author":"SK Tyring","year":"2002","unstructured":"Tyring SK, Baker D, Snowden W (2002) Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years\u2019 experience with acyclovir. J Infect Dis 186(Suppl 1):S40\u2013S46","journal-title":"J Infect Dis"},{"key":"1_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/095632029200300305","volume":"3","author":"LM Beauchamp","year":"1992","unstructured":"Beauchamp LM, Orr GF, de Miranda P, Burnette T, Krenitsky TA (1992) Amino acid ester prodrugs of acyclovir. Antivir Chem Chemother 3:157\u2013164","journal-title":"Antivir Chem Chemother"},{"key":"1_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0166-3542(95)00066-6","volume":"28","author":"KR Beutner","year":"1995","unstructured":"Beutner KR (1995) Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 28:281\u2013290","journal-title":"Antiviral Res"},{"key":"1_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.2165\/00003495-199652050-00009","volume":"52","author":"CM Perry","year":"1996","unstructured":"Perry CM, Faulds D (1996) Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52:754\u2013772","journal-title":"Drugs"},{"key":"1_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/clpt.1993.196","volume":"54","author":"S Weller","year":"1993","unstructured":"Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML (1993) Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 54:595\u2013605","journal-title":"Clin Pharmacol Ther"},{"key":"1_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/095632029300401S01","volume":"4","author":"MR Boyd","year":"1993","unstructured":"Boyd MR, Safrin S, Kern ER (1993) Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern. Antivir Chem Chemother 4:3\u201311","journal-title":"Antivir Chem Chemother"},{"key":"1_CR23","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1128\/AAC.33.10.1765","volume":"33","author":"RA Vere Hodge","year":"1989","unstructured":"Vere Hodge RA, Sutton D, Boyd MR, Harnden MR, Jarvest RL (1989) Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother 33:1765\u20131773","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/0-306-47384-4_14","volume":"11","author":"RL Jarvest","year":"1998","unstructured":"Jarvest RL, Sutton D, Vere Hodge RA (1998) Famciclovir. Discovery and development of a novel antiherpesvirus agent. Pharm Biotechnol 11:313\u2013343","journal-title":"Pharm Biotechnol"},{"key":"1_CR25","first-page":"251","volume":"23","author":"SE Clarke","year":"1995","unstructured":"Clarke SE, Harrell AW, Chenery RJ (1995) Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 23:251\u2013254","journal-title":"Drug Metab Dispos"},{"key":"1_CR26","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","volume":"68","author":"E De Clercq","year":"2004","unstructured":"De Clercq E (2004) Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 68:2301\u20132315","journal-title":"Biochem Pharmacol"},{"key":"1_CR27","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1073\/pnas.76.6.2947","volume":"76","author":"E De Clercq","year":"1979","unstructured":"De Clercq E, Descamps J, De Somer P, Barr PJ, Jones AS, Walker RT (1979) (E)-5-(2-bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A 76:2947\u20132951","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/infdis\/147.3.576","volume":"147","author":"S Shigeta","year":"1983","unstructured":"Shigeta S, Yokota T, Iwabuchi T, Baba M, Konno K, Ogata M, De Clercq E (1983) Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis 147:576\u2013584","journal-title":"J Infect Dis"},{"key":"1_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000150567","volume":"40","author":"P Wutzler","year":"1997","unstructured":"Wutzler P (1997) Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology 40:343\u2013356","journal-title":"Intervirology"},{"key":"1_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/(SICI)1096-9071(199602)48:2<129::AID-JMV2>3.0.CO;2-B","volume":"48","author":"C Dennett","year":"1996","unstructured":"Dennett C, Klapper PE, Cleator GM (1996) Polymerase chain reaction in the investigation of \u201crelapse\u201d following herpes simplex encephalitis. J Med Virol 48:129\u2013132","journal-title":"J Med Virol"},{"key":"1_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0166-3542(03)00064-0","volume":"59","author":"SW Wassilew","year":"2003","unstructured":"Wassilew SW, Wutzler P, Brivddin Herpes Zoster Study Group (2003) Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res 59:57\u201360","journal-title":"Antiviral Res"},{"key":"1_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0166-3542(03)00065-2","volume":"59","author":"SW Wassilew","year":"2003","unstructured":"Wassilew SW, Wutzler P, Brivddin Herpes Zoster Study Group (2003) Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 59:49\u201356","journal-title":"Antiviral Res"},{"key":"1_CR33","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1073\/pnas.82.8.2473","volume":"82","author":"KK Biron","year":"1985","unstructured":"Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, Nelson DJ (1985) Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 82:2473\u20132477","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR34","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1128\/AAC.45.10.2925-2927.2001","volume":"45","author":"JJ McSharry","year":"2001","unstructured":"McSharry JJ, McDonough A, Olson B, Hallenberger S, Reefschlaeger J, Bender W, Drusano GL (2001) Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob Agents Chemother 45:2925\u20132927","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR35","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1128\/AAC.44.10.2811-2815.2000","volume":"44","author":"MD Pescovitz","year":"2000","unstructured":"Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB, O'Grady J, Robinson C, Wren K et al (2000) Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 44:2811\u20132815","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0163-7258(89)90097-1","volume":"40","author":"B Oberg","year":"1989","unstructured":"Oberg B (1989) Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther 40:213\u2013285","journal-title":"Pharmacol Ther"},{"key":"1_CR37","doi-asserted-by":"publisher","first-page":"25246","DOI":"10.1074\/jbc.M111.248864","volume":"286","author":"KE Zahn","year":"2011","unstructured":"Zahn KE, Tchesnokov EP, Gotte M, Doublie S (2011) Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase. J Biol Chem 286:25246\u201325255","journal-title":"J Biol Chem"},{"key":"1_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1128\/AAC.41.3.594","volume":"41","author":"X Xiong","year":"1997","unstructured":"Xiong X, Smith JL, Chen MS (1997) Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 41:594\u2013599","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/095632029600700301","volume":"7","author":"MJM Hitchcock","year":"1996","unstructured":"Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ (1996) Cidofovir, a new agent with potent anti-herpesvirus activity. Antivir Chem Chemother 7:115\u2013127","journal-title":"Antivir Chem Chemother"},{"key":"1_CR40","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/v2102213","volume":"2","author":"KY Hostetler","year":"2010","unstructured":"Hostetler KY (2010) Synthesis and early development of hexadecyloxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2:2213\u20132225","journal-title":"Viruses"},{"key":"1_CR41","doi-asserted-by":"publisher","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","volume":"82","author":"KY Hostetler","year":"2009","unstructured":"Hostetler KY (2009) Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 82:A84\u2013A98","journal-title":"Antiviral Res"},{"key":"1_CR42","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","volume":"49","author":"SL Williams-Aziz","year":"2005","unstructured":"Williams-Aziz SL, Hartline CB, Harden EA, Daily SL, Prichard MN, Kushner NL, Beadle JR, Wan WB, Hostetler KY, Kern ER (2005) Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 49:3724\u20133733","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR43","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","volume":"369","author":"FM Marty","year":"2013","unstructured":"Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM, Brundage TM, Robertson AT, Godkin S, Mommeja-Marin H et al (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369:1227\u20131236","journal-title":"N Engl J Med"},{"key":"1_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","volume":"25","author":"FM Marty","year":"2019","unstructured":"Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME et al (2019) A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic-cell transplantation. Biol Blood Marrow Transplant 25:369\u2013381","journal-title":"Biol Blood Marrow Transplant"},{"key":"1_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12977","volume":"20","author":"YJ Lee","year":"2018","unstructured":"Lee YJ, Neofytos D, Kim SJ, Cheteyan L, Huang YT, Papadopoulos EB, Jakubowski AA, Papanicolaou GA (2018) Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12977","journal-title":"Transpl Infect Dis"},{"key":"1_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1128\/microbiolspec.DMIH2-0007-2015","volume":"4","author":"H Agut","year":"2016","unstructured":"Agut H, Bonnafous P, Gautheret-Dejean A (2016) Human herpesviruses 6A, 6B, and 7. Microbiol Spectr 4:157\u2013176","journal-title":"Microbiol Spectr"},{"key":"1_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1128\/CMR.18.1.217-245.2005","volume":"18","author":"L De Bolle","year":"2005","unstructured":"De Bolle L, Naesens L, De Clercq E (2005) Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 18:217\u2013245","journal-title":"Clin Microbiol Rev"},{"key":"1_CR48","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1182\/blood.2019004315","volume":"135","author":"JA Hill","year":"2020","unstructured":"Hill JA, Nichols WG, Marty FM, Papanicolaou GA, Brundage TM, Lanier R, Zerr DM, Boeckh MJ (2020) Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT. Blood 135:1447\u20131451","journal-title":"Blood"},{"key":"1_CR49","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1172\/JCI119380","volume":"99","author":"DH Kedes","year":"1997","unstructured":"Kedes DH, Ganem D (1997) Sensitivity of Kaposi\u2019s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 99:2082\u20132086","journal-title":"J Clin Invest"},{"key":"1_CR50","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2174\/187152609787847703","volume":"9","author":"G Billaud","year":"2009","unstructured":"Billaud G, Thouvenot D, Morfin F (2009) Drug targets in herpes simplex and Epstein Barr virus infections. Infect Disord Drug Targets 9:117\u2013125","journal-title":"Infect Disord Drug Targets"},{"key":"1_CR51","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","volume":"5","author":"C Gilbert","year":"2002","unstructured":"Gilbert C, Bestman-Smith J, Boivin G (2002) Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 5:88\u2013114","journal-title":"Drug Resist Updat"},{"key":"1_CR52","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1128\/AAC.00615-10","volume":"55","author":"J Piret","year":"2011","unstructured":"Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55:459\u2013472","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/rmv.1787","volume":"24","author":"J Piret","year":"2014","unstructured":"Piret J, Boivin G (2014) Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol 24:186\u2013218","journal-title":"Rev Med Virol"},{"key":"1_CR54","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1093\/nar\/8.24.5949","volume":"8","author":"SL McKnight","year":"1980","unstructured":"McKnight SL (1980) The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene. Nucleic Acids Res 8:5949\u20135964","journal-title":"Nucleic Acids Res"},{"key":"1_CR55","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1099\/0022-1317-71-12-2979","volume":"71","author":"NK Balasubramaniam","year":"1990","unstructured":"Balasubramaniam NK, Veerisetty V, Gentry GA (1990) Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation. J Gen Virol 71:2979\u20132987","journal-title":"J Gen Virol"},{"key":"1_CR56","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1099\/0022-1317-79-9-2083","volume":"79","author":"JS Evans","year":"1998","unstructured":"Evans JS, Lock KP, Levine BA, Champness JN, Sanderson MR, Summers WC, McLeish PJ, Buchan A (1998) Herpesviral thymidine kinases: laxity and resistance by design. J Gen Virol 79:2083\u20132092","journal-title":"J Gen Virol"},{"key":"1_CR57","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1086\/515626","volume":"178","author":"A Gaudreau","year":"1998","unstructured":"Gaudreau A, Hill E, Balfour HH Jr, Erice A, Boivin G (1998) Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 178:297\u2013303","journal-title":"J Infect Dis"},{"key":"1_CR58","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1086\/315696","volume":"182","author":"F Morfin","year":"2000","unstructured":"Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D (2000) Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 182:290\u2013293","journal-title":"J Infect Dis"},{"key":"1_CR59","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1128\/jvi.71.5.3872-3878.1997","volume":"71","author":"JJ Sasadeusz","year":"1997","unstructured":"Sasadeusz JJ, Tufaro F, Safrin S, Schubert K, Hubinette MM, Cheung PK, Sacks SL (1997) Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J Virol 71:3872\u20133878","journal-title":"J Virol"},{"key":"1_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.antiviral.2014.08.013","volume":"111","author":"E Frobert","year":"2014","unstructured":"Frobert E, Burrel S, Ducastelle-Lepretre S, Billaud G, Ader F, Casalegno JS, Nave V, Boutolleau D, Michallet M, Lina B et al (2014) Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France. Antiviral Res 111:36\u201341","journal-title":"Antiviral Res"},{"key":"1_CR61","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.antiviral.2013.09.012","volume":"100","author":"S Burrel","year":"2013","unstructured":"Burrel S, Aime C, Hermet L, Ait-Arkoub Z, Agut H, Boutolleau D (2013) Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey. Antiviral Res 100:365\u2013372","journal-title":"Antiviral Res"},{"key":"1_CR62","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1128\/AAC.46.9.2848-2853.2002","volume":"46","author":"RT Sarisky","year":"2002","unstructured":"Sarisky RT, Bacon T, Boon R, Locke L, Nguyen TT, Leary J, Esser K, Saltzman R (2002) Penciclovir susceptibilities of herpes simplex virus isolates from patients using penciclovir cream for treatment of recurrent herpes labialis. Antimicrob Agents Chemother 46:2848\u20132853","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR63","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00705-003-0124-7","volume":"148","author":"RT Sarisky","year":"2003","unstructured":"Sarisky RT, Bacon TH, Boon RJ, Duffy KE, Esser KM, Leary J, Locke LA, Nguyen TT, Quail MR, Saltzman R (2003) Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 148:1757\u20131769","journal-title":"Arch Virol"},{"key":"1_CR64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/j.1460-2075.1988.tb02781.x","volume":"7","author":"SW Wong","year":"1988","unstructured":"Wong SW, Wahl AF, Yuan PM, Arai N, Pearson BE, Arai K, Korn D, Hunkapiller MW, Wang TS (1988) Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases. EMBO J 7:37\u201347","journal-title":"EMBO J"},{"key":"1_CR65","doi-asserted-by":"publisher","first-page":"11742","DOI":"10.1021\/bi00115a002","volume":"30","author":"J Zhang","year":"1991","unstructured":"Zhang J, Chung DW, Tan CK, Downey KM, Davie EW, So AG (1991) Primary structure of the catalytic subunit of calf thymus DNA polymerase delta: sequence similarities with other DNA polymerases. Biochemistry 30:11742\u201311750","journal-title":"Biochemistry"},{"key":"1_CR66","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3851\/IMP1870","volume":"16","author":"A Sauerbrei","year":"2011","unstructured":"Sauerbrei A, Bohn K, Heim A, Hofmann J, Weissbrich B, Schnitzler P, Hoffmann D, Zell R, Jahn G, Wutzler P et al (2011) Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther 16:1297\u20131308","journal-title":"Antivir Ther"},{"key":"1_CR67","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1086\/314900","volume":"180","author":"I Schmit","year":"1999","unstructured":"Schmit I, Boivin G (1999) Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J Infect Dis 180:487\u2013490","journal-title":"J Infect Dis"},{"key":"1_CR68","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/jmv.2195","volume":"67","author":"J Bestman-Smith","year":"2002","unstructured":"Bestman-Smith J, Boivin G (2002) Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy. J Med Virol 67:88\u201391","journal-title":"J Med Virol"},{"key":"1_CR69","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1128\/JVI.77.14.7820-7829.2003","volume":"77","author":"J Bestman-Smith","year":"2003","unstructured":"Bestman-Smith J, Boivin G (2003) Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 77:7820\u20137829","journal-title":"J Virol"},{"key":"1_CR70","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1128\/JVI.06620-11","volume":"86","author":"G Andrei","year":"2012","unstructured":"Andrei G, Topalis D, Fiten P, McGuigan C, Balzarini J, Opdenakker G, Snoeck R (2012) In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs. J Virol 86:2641\u20132652","journal-title":"J Virol"},{"key":"1_CR71","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/infdis\/170.1.68","volume":"170","author":"G Boivin","year":"1994","unstructured":"Boivin G, Edelman CK, Pedneault L, Talarico CL, Biron KK, Balfour HH Jr (1994) Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 170:68\u201375","journal-title":"J Infect Dis"},{"key":"1_CR72","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1128\/AAC.43.10.2412","volume":"43","author":"F Morfin","year":"1999","unstructured":"Morfin F, Thouvenot D, De Turenne-Tessier M, Lina B, Aymard M, Ooka T (1999) Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir. Antimicrob Agents Chemother 43:2412\u20132416","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR73","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/cid\/cis879","volume":"56","author":"MT van der Beek","year":"2013","unstructured":"van der Beek MT, Vermont CL, Bredius RG, Marijt EW, van der Blij-de Brouwer CS, Kroes AC, Claas EC, Vossen AC (2013) Persistence and antiviral resistance of VZV in hematological patients. Clin Infect Dis 56:335\u2013343","journal-title":"Clin Infect Dis"},{"key":"1_CR74","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/(SICI)1096-9071(199807)55:3<250::AID-JMV12>3.0.CO;2-K","volume":"55","author":"AM Fillet","year":"1998","unstructured":"Fillet AM, Dumont B, Caumes E, Visse B, Agut H, Bricaire F, Huraux JM (1998) Acyclovir-resistant varicella-zoster virus: phenotypic and genetic characterization. J Med Virol 55:250\u2013254","journal-title":"J Med Virol"},{"key":"1_CR75","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1086\/324503","volume":"33","author":"E Saint-Leger","year":"2001","unstructured":"Saint-Leger E, Caumes E, Breton G, Douard D, Saiag P, Huraux JM, Bricaire F, Agut H, Fillet AM (2001) Clinical and virologic characterization of acyclovir-resistant varicella-zoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 33:2061\u20132067","journal-title":"Clin Infect Dis"},{"key":"1_CR76","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.antiviral.2011.04.005","volume":"90","author":"A Sauerbrei","year":"2011","unstructured":"Sauerbrei A, Taut J, Zell R, Wutzler P (2011) Resistance testing of clinical varicella-zoster virus strains. Antiviral Res 90:242\u2013247","journal-title":"Antiviral Res"},{"key":"1_CR77","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1099\/0022-1317-69-10-2585","volume":"69","author":"MH Sawyer","year":"1988","unstructured":"Sawyer MH, Inchauspe G, Biron KK, Waters DJ, Straus SE, Ostrove JM (1988) Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus. J Gen Virol 69:2585\u20132593","journal-title":"J Gen Virol"},{"key":"1_CR78","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1128\/jvi.67.2.1024-1033.1993","volume":"67","author":"CL Talarico","year":"1993","unstructured":"Talarico CL, Phelps WC, Biron KK (1993) Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 67:1024\u20131033","journal-title":"J Virol"},{"key":"1_CR79","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1099\/0022-1317-82-11-2761","volume":"82","author":"T Kamiyama","year":"2001","unstructured":"Kamiyama T, Kurokawa M, Shiraki K (2001) Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol 82:2761\u20132765","journal-title":"J Gen Virol"},{"key":"1_CR80","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1086\/514257","volume":"178","author":"B Visse","year":"1998","unstructured":"Visse B, Dumont B, Huraux JM, Fillet AM (1998) Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS. J Infect Dis 178:S55\u2013S57","journal-title":"J Infect Dis"},{"key":"1_CR81","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.antiviral.2012.09.016","volume":"96","author":"S Burrel","year":"2012","unstructured":"Burrel S, Bonnafous P, Hubacek P, Agut H, Boutolleau D (2012) Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity. Antiviral Res 96:386\u2013390","journal-title":"Antiviral Res"},{"key":"1_CR82","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.antiviral.2012.07.001","volume":"95","author":"N Malartre","year":"2012","unstructured":"Malartre N, Boulieu R, Falah N, Cortay JC, Lina B, Morfin F, Frobert E (2012) Effects of mutations on herpes simplex virus 1 thymidine kinase functionality: an in vitro assay based on detection of monophosphate forms of acyclovir and thymidine using HPLC\/DAD. Antiviral Res 95:224\u2013228","journal-title":"Antiviral Res"},{"key":"1_CR83","first-page":"115","volume":"4","author":"JC Pottage","year":"1995","unstructured":"Pottage JC, Kessler HA (1995) Herpes simplex virus resistance to acyclovir: clinical relevance. Infect Agents Dis 4:115\u2013124","journal-title":"Infect Agents Dis"},{"key":"1_CR84","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1128\/jvi.65.12.6407-6413.1991","volume":"65","author":"GB Roberts","year":"1991","unstructured":"Roberts GB, Fyfe JA, Gaillard RK, Short SA (1991) Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. J Virol 65:6407\u20136413","journal-title":"J Virol"},{"key":"1_CR85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.antiviral.2012.08.001","volume":"96","author":"A Sauerbrei","year":"2012","unstructured":"Sauerbrei A, Liermann K, Bohn K, Henke A, Zell R, Gronowitz S, Wutzler P (2012) Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antiviral Res 96:105\u2013107","journal-title":"Antiviral Res"},{"key":"1_CR86","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jviromet.2012.12.001","volume":"188","author":"A Sauerbrei","year":"2013","unstructured":"Sauerbrei A, Vodisch S, Bohn K, Schacke M, Gronowitz S (2013) Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTumR assay. J Virol Methods 188:70\u201372","journal-title":"J Virol Methods"},{"key":"1_CR87","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/rmv.1873","volume":"26","author":"AB Campos","year":"2016","unstructured":"Campos AB, Ribeiro J, Boutolleau D, Sousa H (2016) Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art. Rev Med Virol 26:161\u2013182","journal-title":"Rev Med Virol"},{"key":"1_CR88","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1128\/CMR.00009-10","volume":"23","author":"NS Lurain","year":"2010","unstructured":"Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:689\u2013712","journal-title":"Clin Microbiol Rev"},{"key":"1_CR89","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1126\/science.3291115","volume":"241","author":"SK Hanks","year":"1988","unstructured":"Hanks SK, Quinn AM, Hunter T (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42\u201352","journal-title":"Science"},{"key":"1_CR90","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A, The Transplantation Society International CMV Consensus Group (2018) The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102:900\u2013931","journal-title":"Transplantation"},{"key":"1_CR91","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1128\/AAC.00736-07","volume":"51","author":"S Chou","year":"2007","unstructured":"Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A (2007) Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 51:4160\u20134162","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR92","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1128\/JCM.02205-14","volume":"52","author":"E Drouot","year":"2014","unstructured":"Drouot E, Piret J, Lebel MH, Boivin G (2014) Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. J Clin Microbiol 52:4043\u20134046","journal-title":"J Clin Microbiol"},{"key":"1_CR93","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1128\/AAC.00062-13","volume":"57","author":"SH James","year":"2013","unstructured":"James SH, Price NB, Hartline CB, Lanier ER, Prichard MN (2013) Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother 57:3321\u20133325","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR94","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1128\/AAC.00214-16","volume":"60","author":"S Chou","year":"2016","unstructured":"Chou S, Ercolani RJ, Lanier ER (2016) Novel cytomegalovirus UL54 DNA polymerase gene mutations selected in vitro that confer brincidofovir resistance. Antimicrob Agents Chemother 60:3845\u20133848","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR95","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/infdis\/jiw073","volume":"214","author":"ER Lanier","year":"2016","unstructured":"Lanier ER, Foster S, Brundage T, Chou S, Prichard MN, Kleiboeker S, Wilson C, Colville D, Mommeja-Marin H (2016) Analysis of mutations in the gene encoding cytomegalovirus DNA polymerase in a phase 2 clinical trial of brincidofovir prophylaxis. J Infect Dis 214:32\u201335","journal-title":"J Infect Dis"},{"key":"1_CR96","first-page":"3624146","volume":"2017","author":"R Vial","year":"2017","unstructured":"Vial R, Zandotti C, Alain S, Decourt A, Jourde-Chiche N, Purgus R, Bornet C, Daniel L, Moal V, Legris T (2017) Brincidofovir use after foscarnet crystal nephropathy in a kidney transplant recipient with multiresistant cytomegalovirus infection. Case Rep Transplant 2017:3624146","journal-title":"Case Rep Transplant"},{"key":"1_CR97","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1086\/317929","volume":"183","author":"JC Mendez","year":"2001","unstructured":"Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS, Ilstrup D, Paya CV (2001) Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 183:179\u2013184","journal-title":"J Infect Dis"},{"key":"1_CR98","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1099\/0022-1317-82-11-2767","volume":"82","author":"C Manichanh","year":"2001","unstructured":"Manichanh C, Olivier-Aubron C, Lagarde JP, Aubin JT, Bossi P, Gautheret-Dejean A, Huraux JM, Agut H (2001) Selection of the same mutation in the U69 protein kinase gene of human herpesvirus-6 after prolonged exposure to ganciclovir in vitro and in vivo. J Gen Virol 82:2767\u20132776","journal-title":"J Gen Virol"},{"key":"1_CR99","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jviromet.2009.06.016","volume":"161","author":"K Nakano","year":"2009","unstructured":"Nakano K, Nishinaka K, Tanaka T, Ohshima A, Sugimoto N, Isegawa Y (2009) Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography. J Virol Methods 161:223\u2013230","journal-title":"J Virol Methods"},{"key":"1_CR100","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jmv.10510","volume":"71","author":"D Safronetz","year":"2003","unstructured":"Safronetz D, Petric M, Tellier R, Parvez B, Tipples GA (2003) Mapping ganciclovir resistance in the human herpesvirus-6 U69 protein kinase. J Med Virol 71:434\u2013439","journal-title":"J Med Virol"},{"key":"1_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.antiviral.2004.04.009","volume":"64","author":"L De Bolle","year":"2004","unstructured":"De Bolle L, Manichanh C, Agut H, De Clercq E, Naesens L (2004) Human herpesvirus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral Res 64:17\u201325","journal-title":"Antiviral Res"},{"key":"1_CR102","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1177\/135965350701200608","volume":"12","author":"P Bonnafous","year":"2007","unstructured":"Bonnafous P, Naesens L, Petrella S, Gautheret-Dejean A, Boutolleau D, Sougakoff W, Agut H (2007) Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther 12:877\u2013888","journal-title":"Antivir Ther"},{"key":"1_CR103","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.antiviral.2007.12.004","volume":"77","author":"P Bonnafous","year":"2008","unstructured":"Bonnafous P, Boutolleau D, Naesens L, Deback C, Gautheret-Dejean A, Agut H (2008) Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection. Antiviral Res 77:237\u2013240","journal-title":"Antiviral Res"},{"key":"1_CR104","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1128\/JVI.01955-12","volume":"87","author":"EM Borst","year":"2013","unstructured":"Borst EM, Kleine-Albers J, Gabaev I, Babic M, Wagner K, Binz A, Degenhardt I, Kalesse M, Jonjic S, Bauerfeind R et al (2013) The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol 87:1720\u20131732","journal-title":"J Virol"},{"key":"1_CR105","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1128\/JVI.72.3.2259-2264.1998","volume":"72","author":"E Bogner","year":"1998","unstructured":"Bogner E, Radsak K, Stinski MF (1998) The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J Virol 72:2259\u20132264","journal-title":"J Virol"},{"key":"1_CR106","doi-asserted-by":"publisher","first-page":"14660","DOI":"10.1128\/JVI.79.23.14660-14667.2005","volume":"79","author":"A Dittmer","year":"2005","unstructured":"Dittmer A, Drach JC, Townsend LB, Fischer A, Bogner E (2005) Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J Virol 79:14660\u201314667","journal-title":"J Virol"},{"key":"1_CR107","doi-asserted-by":"publisher","first-page":"6943","DOI":"10.1074\/jbc.M108984200","volume":"277","author":"JS Hwang","year":"2002","unstructured":"Hwang JS, Bogner E (2002) ATPase activity of the terminase subunit pUL56 of human cytomegalovirus. J Biol Chem 277:6943\u20136948","journal-title":"J Biol Chem"},{"key":"1_CR108","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1093\/nar\/gkg229","volume":"31","author":"B Scholz","year":"2003","unstructured":"Scholz B, Rechter S, Drach JC, Townsend LB, Bogner E (2003) Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res 31:1426\u20131433","journal-title":"Nucleic Acids Res"},{"key":"1_CR109","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/nar\/30.7.1695","volume":"30","author":"H Scheffczik","year":"2002","unstructured":"Scheffczik H, Savva CG, Holzenburg A, Kolesnikova L, Bogner E (2002) The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res 30:1695\u20131703","journal-title":"Nucleic Acids Res"},{"key":"1_CR110","doi-asserted-by":"crossref","unstructured":"Neuber S, Wagner K, Goldner T, Lischka P, Steinbrueck L, Messerle M, Borst EM (2017) Mutual interplay between the human cytomegalovirus terminase subunits pUL51, pUL56, and pUL89 promotes terminase complex formation. J Virol 91:e02384\u201316","DOI":"10.1128\/JVI.02384-16"},{"key":"1_CR111","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1128\/AAC.48.5.1647-1651.2004","volume":"48","author":"MR Underwood","year":"2004","unstructured":"Underwood MR, Ferris RG, Selleseth DW, Davis MG, Drach JC, Townsend LB, Biron KK, Boyd FL (2004) Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother 48:1647\u20131651","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR112","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1128\/JVI.72.1.717-725.1998","volume":"72","author":"MR Underwood","year":"1998","unstructured":"Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB, Biron KK (1998) Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol 72:717\u2013725","journal-title":"J Virol"},{"key":"1_CR113","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jac\/48.6.757","volume":"48","author":"J Reefschlaeger","year":"2001","unstructured":"Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, Haerter M, Buerger I, Trappe J, Herrington JA et al (2001) Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 48:757\u2013767","journal-title":"J Antimicrob Chemother"},{"key":"1_CR114","unstructured":"Nagelschmitz J, Moeller JG, Stass H, Wandel C, Kuhlmann J (1999) Safety, tolerability and pharmacokinetics of single oral doses of BAY 38-4766\u2013a novel, non-nucleosidic inhibitor of human cytomegalovirus replication\u2013in healthy male subjects. In: 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, CA"},{"key":"1_CR115","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1128\/AAC.01596-09","volume":"54","author":"P Lischka","year":"2010","unstructured":"Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H (2010) In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 54:1290\u20131297","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR116","doi-asserted-by":"publisher","first-page":"10884","DOI":"10.1128\/JVI.05265-11","volume":"85","author":"T Goldner","year":"2011","unstructured":"Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P (2011) The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 85:10884\u201310893","journal-title":"J Virol"},{"key":"1_CR117","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1128\/AAC.05908-11","volume":"56","author":"M Marschall","year":"2012","unstructured":"Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, Lischka P (2012) In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 56:1135\u20131137","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR118","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1128\/AAC.00114-15","volume":"59","author":"S Wildum","year":"2015","unstructured":"Wildum S, Zimmermann H, Lischka P (2015) In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother 59:3140\u20133148","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR119","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3851\/IMP3028","volume":"21","author":"E Drouot","year":"2016","unstructured":"Drouot E, Piret J, Boivin G (2016) Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. Antivir Ther 21:535\u2013539","journal-title":"Antivir Ther"},{"key":"1_CR120","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cts.12483","volume":"10","author":"K Erb-Zohar","year":"2017","unstructured":"Erb-Zohar K, Kropeit D, Scheuenpflug J, Stobernack HP, Hulskotte E, van Schanke A, Zimmermann H, Rubsamen-Schaeff H (2017) Intravenous hydroxypropyl beta-cyclodextrin formulation of letermovir: a phase I, randomized, single-ascending, and multiple-dose trial. Clin Transl Sci 10:487\u2013495","journal-title":"Clin Transl Sci"},{"key":"1_CR121","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","volume":"11","author":"DR Kaul","year":"2011","unstructured":"Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P, Zimmermann H, Rubsamen-Schaeff H (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 11:1079\u20131084","journal-title":"Am J Transplant"},{"key":"1_CR122","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12965","volume":"20","author":"PP Chong","year":"2018","unstructured":"Chong PP, Teiber D, Prokesch BC, Arasaratnam RJ, Peltz M, Drazner MH, Garg S (2018) Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation). Transpl Infect Dis 20:e12965","journal-title":"Transpl Infect Dis"},{"key":"1_CR123","doi-asserted-by":"crossref","unstructured":"Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW, Maziarz EK, Saullo JH, Wolfe CR (2019) Use of letermovir as salvage therapy for drug-resistant CMV retinitis: a case series. Antimicrob Agents Chemother 63:e02337\u201318","DOI":"10.1128\/AAC.02337-18"},{"key":"1_CR124","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/TP.0000000000002785","volume":"104","author":"P Phoompoung","year":"2020","unstructured":"Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D, Humar A (2020) Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation 104:404\u2013409","journal-title":"Transplantation"},{"key":"1_CR125","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/135965350801300504","volume":"13","author":"G Champier","year":"2008","unstructured":"Champier G, Couvreux A, Hantz S, Rametti A, Mazeron MC, Bouaziz S, Denis F, Alain S (2008) Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. Antivir Ther 13:643\u2013654","journal-title":"Antivir Ther"},{"key":"1_CR126","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/135965350701200209","volume":"12","author":"G Champier","year":"2007","unstructured":"Champier G, Hantz S, Couvreux A, Stuppfler S, Mazeron MC, Bouaziz S, Denis F, Alain S (2007) New functional domains of human cytomegalovirus pUL89 predicted by sequence analysis and three-dimensional modelling of the catalytic site DEXDc. Antivir Ther 12:217\u2013232","journal-title":"Antivir Ther"},{"key":"1_CR127","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1093\/nar\/gkf524","volume":"30","author":"MS Mitchell","year":"2002","unstructured":"Mitchell MS, Matsuzaki S, Imai S, Rao VB (2002) Sequence analysis of bacteriophage T4 DNA packaging\/terminase genes 16 and 17 reveals a common ATPase center in the large subunit of viral terminases. Nucleic Acids Res 30:4009\u20134021","journal-title":"Nucleic Acids Res"},{"key":"1_CR128","doi-asserted-by":"crossref","unstructured":"Chou S (2017) Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds. Antimicrob Agents Chemother 61:e01325-17","DOI":"10.1128\/AAC.01325-17"},{"key":"1_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","volume":"148","author":"S Chou","year":"2017","unstructured":"Chou S (2017) A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Res 148:1\u20134","journal-title":"Antiviral Res"},{"key":"1_CR130","first-page":"2253","volume":"75","author":"S Alain","year":"2020","unstructured":"Alain S, Feghoul L, Girault S, Lepiller Q, Frobert E, Michonneau D, Berceanu A, Ducastelle-Lepretre S, Tilloy V, Guerin E et al (2020) Letermovir breakthroughs during the French Named Patient Programme: interest of monitoring blood concentration in clinical practice. J Antimicrob Chemother 75:2253\u20132257","journal-title":"J Antimicrob Chemother"},{"key":"1_CR131","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/infdis\/jiz577","volume":"221","author":"CM Douglas","year":"2020","unstructured":"Douglas CM, Barnard R, Holder D, Leavitt R, Levitan D, Maguire M, Nickle D, Teal V, Wan H, van Alewijk D et al (2020) Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients. J Infect Dis 221:1117\u20131126","journal-title":"J Infect Dis"},{"key":"1_CR132","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiv352","volume":"213","author":"P Lischka","year":"2016","unstructured":"Lischka P, Michel D, Zimmermann H (2016) Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis 213:23\u201330","journal-title":"J Infect Dis"},{"key":"1_CR133","unstructured":"Marty FM, Ljungman PT, Chemaly RF (2017) A phase III randomized, double-blind, placebo-controlled trial of letermovir for prevention of cytomegalovirus infection in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. In: BMT Tandem Meetings. Abstract LBA2. Orlando, FL"},{"key":"1_CR134","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","volume":"26","author":"C Robin","year":"2020","unstructured":"Robin C, Thiebaut A, Alain S, Sicre de Fontbrune F, Berceanu A, D\u2019Aveni M, Ceballos P, Redjoul R, Nguyen-Quoc S, Benard N et al (2020) Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program. Biol Blood Marrow Transplant 26:978\u2013984","journal-title":"Biol Blood Marrow Transplant"},{"key":"1_CR135","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41409-018-0389-9","volume":"54","author":"BM Knoll","year":"2018","unstructured":"Knoll BM, Seiter K, Phillips A, Soave R (2018) Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. Bone Marrow Transplant 54:911\u2013912","journal-title":"Bone Marrow Transplant"},{"key":"1_CR136","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1111\/ajt.15135","volume":"18","author":"L Cherrier","year":"2018","unstructured":"Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S (2018) Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant 18:3060\u20133064","journal-title":"Am J Transplant"},{"key":"1_CR137","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12879-019-4016-1","volume":"19","author":"S Jung","year":"2019","unstructured":"Jung S, Michel M, Stamminger T, Michel D (2019) Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis 19:388","journal-title":"BMC Infect Dis"},{"key":"1_CR138","doi-asserted-by":"publisher","first-page":"ofz375","DOI":"10.1093\/ofid\/ofz375","volume":"6","author":"S Popping","year":"2019","unstructured":"Popping S, Dalm V, Lubke N, Cristanziano VD, Kaiser R, Boucher CAB, Van Kampen JJA (2019) Emergence and persistence of letermovir-resistant cytomegalovirus in a patient with primary immunodeficiency. Open Forum Infect Dis 6:ofz375","journal-title":"Open Forum Infect Dis"},{"key":"1_CR139","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/infdis\/jiz642","volume":"221","author":"H Jo","year":"2020","unstructured":"Jo H, Kwon DE, Han SH, Min SY, Hong YM, Lim BJ, Lee KH, Jo JH (2020) De Novo genotypic heterogeneity in the UL56 region in cytomegalovirus-infected tissues: implications for primary letermovir resistance. J Infect Dis 221:1480\u20131487","journal-title":"J Infect Dis"},{"key":"1_CR140","doi-asserted-by":"publisher","first-page":"6340","DOI":"10.1128\/jvi.70.9.6340-6346.1996","volume":"70","author":"D Michel","year":"1996","unstructured":"Michel D, Pavic I, Zimmermann A, Haupt E, Wunderlich K, Heuschmid M, Mertens T (1996) The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J Virol 70:6340\u20136346","journal-title":"J Virol"},{"key":"1_CR141","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.1128\/JVI.00497-07","volume":"81","author":"JP Kamil","year":"2007","unstructured":"Kamil JP, Coen DM (2007) Human cytomegalovirus protein kinase UL97 forms a complex with the tegument phosphoprotein pp65. J Virol 81:10659\u201310668","journal-title":"J Virol"},{"key":"1_CR142","doi-asserted-by":"publisher","first-page":"7393","DOI":"10.1128\/JVI.02825-12","volume":"87","author":"TM Bigley","year":"2013","unstructured":"Bigley TM, Reitsma JM, Mirza SP, Terhune SS (2013) Human cytomegalovirus pUL97 regulates the viral major immediate early promoter by phosphorylation-mediated disruption of histone deacetylase 1 binding. J Virol 87:7393\u20137408","journal-title":"J Virol"},{"key":"1_CR143","doi-asserted-by":"publisher","first-page":"7720","DOI":"10.1128\/JVI.77.14.7720-7727.2003","volume":"77","author":"PM Krosky","year":"2003","unstructured":"Krosky PM, Baek MC, Jahng WJ, Barrera I, Harvey RJ, Biron KK, Coen DM, Sethna PB (2003) The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 77:7720\u20137727","journal-title":"J Virol"},{"key":"1_CR144","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0042-6822(03)00147-8","volume":"311","author":"M Marschall","year":"2003","unstructured":"Marschall M, Freitag M, Suchy P, Romaker D, Kupfer R, Hanke M, Stamminger T (2003) The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311:60\u201371","journal-title":"Virology"},{"key":"1_CR145","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1099\/vir.0.022293-0","volume":"91","author":"S Becke","year":"2010","unstructured":"Becke S, Fabre-Mersseman V, Aue S, Auerochs S, Sedmak T, Wolfrum U, Strand D, Marschall M, Plachter B, Reyda S (2010) Modification of the major tegument protein pp65 of human cytomegalovirus inhibits virus growth and leads to the enhancement of a protein complex with pUL69 and pUL97 in infected cells. J Gen Virol 91:2531\u20132541","journal-title":"J Gen Virol"},{"key":"1_CR146","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1099\/vir.0.005827-0","volume":"90","author":"M Thomas","year":"2009","unstructured":"Thomas M, Rechter S, Milbradt J, Auerochs S, Muller R, Stamminger T, Marschall M (2009) Cytomegaloviral protein kinase pUL97 interacts with the nuclear mRNA export factor pUL69 to modulate its intranuclear localization and activity. J Gen Virol 90:567\u2013578","journal-title":"J Gen Virol"},{"key":"1_CR147","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1128\/JVI.00007-13","volume":"87","author":"NI Reim","year":"2013","unstructured":"Reim NI, Kamil JP, Wang D, Lin A, Sharma M, Ericsson M, Pesola JM, Golan DE, Coen DM (2013) Inactivation of retinoblastoma protein does not overcome the requirement for human cytomegalovirus UL97 in lamina disruption and nuclear egress. J Virol 87:5019\u20135027","journal-title":"J Virol"},{"key":"1_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000275","volume":"5","author":"S Hamirally","year":"2009","unstructured":"Hamirally S, Kamil JP, Ndassa-Colday YM, Lin AJ, Jahng WJ, Baek MC, Noton S, Silva LA, Simpson-Holley M, Knipe DM et al (2009) Viral mimicry of Cdc2\/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog 5:e1000275","journal-title":"PLoS Pathog"},{"key":"1_CR149","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1128\/JVI.02426-14","volume":"89","author":"M Sharma","year":"2015","unstructured":"Sharma M, Bender BJ, Kamil JP, Lye MF, Pesola JM, Reim NI, Hogle JM, Coen DM (2015) Human cytomegalovirus UL97 phosphorylates the viral nuclear egress complex. J Virol 89:523\u2013534","journal-title":"J Virol"},{"key":"1_CR150","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/rmv.615","volume":"19","author":"MN Prichard","year":"2009","unstructured":"Prichard MN (2009) Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 19:215\u2013229","journal-title":"Rev Med Virol"},{"key":"1_CR151","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1128\/jvi.71.1.405-411.1997","volume":"71","author":"Z He","year":"1997","unstructured":"He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DM (1997) The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J Virol 71:405\u2013411","journal-title":"J Virol"},{"key":"1_CR152","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","volume":"47","author":"SL Williams","year":"2003","unstructured":"Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER (2003) In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 47:2186\u20132192","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR153","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","volume":"46","author":"KK Biron","year":"2002","unstructured":"Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE et al (2002) Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 46:2365\u20132372","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR154","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","volume":"37","author":"WL Drew","year":"2006","unstructured":"Drew WL, Miner RC, Marousek GI, Chou S (2006) Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 37:124\u2013127","journal-title":"J Clin Virol"},{"key":"1_CR155","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1128\/JVI.73.7.5663-5670.1999","volume":"73","author":"MN Prichard","year":"1999","unstructured":"Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, Parker BO, Pari GS (1999) A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 73:5663\u20135670","journal-title":"J Virol"},{"key":"1_CR156","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1099\/0022-1317-82-6-1439","volume":"82","author":"M Marschall","year":"2001","unstructured":"Marschall M, Stein-Gerlach M, Freitag M, Kupfer R, van Den Bogaard M, Stamminger T (2001) Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J Gen Virol 82:1439\u20131450","journal-title":"J Gen Virol"},{"key":"1_CR157","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1128\/JVI.77.2.905-914.2003","volume":"77","author":"PM Krosky","year":"2003","unstructured":"Krosky PM, Baek MC, Coen DM (2003) The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 77:905\u2013914","journal-title":"J Virol"},{"key":"1_CR158","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2042-4280-1-4","volume":"1","author":"CD Shannon-Lowe","year":"2010","unstructured":"Shannon-Lowe CD, Emery VC (2010) The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae 1:4","journal-title":"Herpesviridae"},{"key":"1_CR159","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1128\/JVI.01787-07","volume":"82","author":"S Chou","year":"2008","unstructured":"Chou S, Marousek GI (2008) Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol 82:246\u2013253","journal-title":"J Virol"},{"key":"1_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.01.003","volume":"37","author":"D Topalis","year":"2018","unstructured":"Topalis D, Gillemot S, Snoeck R, Andrei G (2018) Thymidine kinase and protein kinase in drug-resistant herpesviruses: heads of a lernaean hydra. Drug Resist Updat 37:1\u201316","journal-title":"Drug Resist Updat"},{"key":"1_CR161","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1128\/AAC.00577-06","volume":"50","author":"S Chou","year":"2006","unstructured":"Chou S, Marousek GI (2006) Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 50:3470\u20133472","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR162","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","volume":"157","author":"S Chou","year":"2018","unstructured":"Chou S, Ercolani RJ, Derakhchan K (2018) Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Antiviral Res 157:128\u2013133","journal-title":"Antiviral Res"},{"key":"1_CR163","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","volume":"158","author":"MS O\u2019Brien","year":"2018","unstructured":"O\u2019Brien MS, Markovich KC, Selleseth D, DeVita AV, Sethna P, Gentry BG (2018) In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. Antiviral Res 158:255\u2013263","journal-title":"Antiviral Res"},{"key":"1_CR164","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/15257770008032999","volume":"19","author":"JH Chan","year":"2000","unstructured":"Chan JH, Chamberlain SD, Biron KK, Davis MG, Harvey RJ, Selleseth DW, Dornsife RE, Dark EH, Frick LW, Townsend LB et al (2000) Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94). Nucleosides Nucleotides Nucleic Acids 19:101\u2013123","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"1_CR165","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","volume":"46","author":"GW Koszalka","year":"2002","unstructured":"Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, Drach JC, Biron KK (2002) Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 46:2373\u20132380","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR166","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","volume":"12","author":"DJ Winston","year":"2012","unstructured":"Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG et al (2012) Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 12:3021\u20133030","journal-title":"Am J Transplant"},{"key":"1_CR167","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1093\/ofid\/ofw172.1834","volume":"3","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Cordonnier C, Jaksch P, Poir\u00e9 X, Wu JJ, Wijatyk A, Saliba F, Witzke O, Villano S (2016) Maribavir versus valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients. Open Forum Infec Dis 3:2287","journal-title":"Open Forum Infec Dis"},{"key":"1_CR168","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/cid\/ciy706","volume":"68","author":"GA Papanicolaou","year":"2018","unstructured":"Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM et al (2018) Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis 68:1255\u20131264","journal-title":"Clin Infect Dis"},{"key":"1_CR169","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/135965350901400510","volume":"14","author":"S Hantz","year":"2009","unstructured":"Hantz S, Couvreux A, Champier G, Trapes L, Cotin S, Denis F, Bouaziz S, Alain S (2009) Conserved domains and structure prediction of human cytomegalovirus UL27 protein. Antivir Ther 14:663\u2013672","journal-title":"Antivir Ther"},{"key":"1_CR170","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1743-422X-3-18","volume":"3","author":"MN Prichard","year":"2006","unstructured":"Prichard MN, Quenelle DC, Bidanset DJ, Komazin G, Chou S, Drach JC, Kern ER (2006) Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice. Virol J 3:18","journal-title":"Virol J"},{"key":"1_CR171","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.chom.2011.01.006","volume":"9","author":"JM Reitsma","year":"2011","unstructured":"Reitsma JM, Savaryn JP, Faust K, Sato H, Halligan BD, Terhune SS (2011) Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. Cell Host Microbe 9:103\u2013114","journal-title":"Cell Host Microbe"},{"key":"1_CR172","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.chom.2011.02.001","volume":"9","author":"JP Kamil","year":"2011","unstructured":"Kamil JP, Coen DM (2011) HATs on for drug resistance. Cell Host Microbe 9:85\u201387","journal-title":"Cell Host Microbe"},{"key":"1_CR173","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1128\/AAC.01177-08","volume":"53","author":"S Chou","year":"2009","unstructured":"Chou S (2009) Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother 53:81\u201385","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR174","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.3389\/fmicb.2016.01317","volume":"7","author":"CJ Houldcroft","year":"2016","unstructured":"Houldcroft CJ, Bryant JM, Depledge DP, Margetts BK, Simmonds J, Nicolaou S, Tutill HJ, Williams R, Worth AJ, Marks SD et al (2016) Detection of low frequency multi-drug resistance and novel putative maribavir resistance in immunocompromised pediatric patients with cytomegalovirus. Front Microbiol 7:1317","journal-title":"Front Microbiol"},{"key":"1_CR175","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1086\/653122","volume":"202","author":"L Strasfeld","year":"2010","unstructured":"Strasfeld L, Lee I, Tatarowicz W, Villano S, Chou S (2010) Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis 202:104\u2013108","journal-title":"J Infect Dis"},{"key":"1_CR176","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1128\/AAC.49.3.1039-1045.2005","volume":"49","author":"ER Kern","year":"2005","unstructured":"Kern ER, Kushner NL, Hartline CB, Williams-Aziz SL, Harden EA, Zhou S, Zemlicka J, Prichard MN (2005) In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 49:1039\u20131045","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR177","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/jm030316s","volume":"47","author":"S Zhou","year":"2004","unstructured":"Zhou S, Breitenbach JM, Borysko KZ, Drach JC, Kern ER, Gullen E, Cheng YC, Zemlicka J (2004) Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides. J Med Chem 47:566\u2013575","journal-title":"J Med Chem"},{"key":"1_CR178","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1128\/AAC.00571-11","volume":"55","author":"SH James","year":"2011","unstructured":"James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Bowlin TL, Kern ER, Prichard MN (2011) Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother 55:4682\u20134691","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR179","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1128\/AAC.00468-10","volume":"54","author":"BG Gentry","year":"2010","unstructured":"Gentry BG, Kamil JP, Coen DM, Zemlicka J, Drach JC (2010) Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir. Antimicrob Agents Chemother 54:3093\u20133098","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR180","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1128\/AAC.02311-13","volume":"58","author":"BG Gentry","year":"2014","unstructured":"Gentry BG, Drach JC (2014) Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells. Antimicrob Agents Chemother 58:2329\u20132333","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR181","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/AAC.00449-16","volume":"60","author":"H Chen","year":"2016","unstructured":"Chen H, Li C, Zemlicka J, Gentry BG, Bowlin TL, Coen DM (2016) Potency and stereoselectivity of cyclopropavir triphosphate action on human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother 60:4176\u20134182","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR182","doi-asserted-by":"crossref","unstructured":"Rouphael NG, Hurwitz SJ, Hart M, Beck A, Anderson EJ, Deye G, Osborn B, Cai SY, Focht C, Amegashie C et al (2019) Phase Ib trial to evaluate the safety and pharmacokinetics of multiple ascending doses of filociclovir (MBX-400, cyclopropavir) in healthy volunteers. Antimicrob Agents Chemother 63:e00717\u201319","DOI":"10.1128\/AAC.00717-19"},{"key":"1_CR183","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1128\/AAC.01259-10","volume":"55","author":"S Chou","year":"2011","unstructured":"Chou S, Bowlin TL (2011) Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob Agents Chemother 55:382\u2013384","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR184","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1128\/AAC.00214-13","volume":"57","author":"BG Gentry","year":"2013","unstructured":"Gentry BG, Vollmer LE, Hall ED, Borysko KZ, Zemlicka J, Kamil JP, Drach JC (2013) Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97. Antimicrob Agents Chemother 57:4343\u20134348","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR185","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1128\/AAC.05559-11","volume":"56","author":"S Chou","year":"2012","unstructured":"Chou S, Marousek G, Bowlin TL (2012) Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother 56:197\u2013201","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR186","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/nm0402-386","volume":"8","author":"JJ Crute","year":"2002","unstructured":"Crute JJ, Grygon CA, Hargrave KD, Simoneau B, Faucher AM, Bolger G, Kibler P, Liuzzi M, Cordingley MG (2002) Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 8:386\u2013391","journal-title":"Nat Med"},{"key":"1_CR187","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm0402-392","volume":"8","author":"G Kleymann","year":"2002","unstructured":"Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, Handke G, Eckenberg P, Hewlett G, Pevzner V et al (2002) New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 8:392\u2013398","journal-title":"Nat Med"},{"key":"1_CR188","first-page":"46","volume":"10","author":"G Kleymann","year":"2003","unstructured":"Kleymann G (2003) New antiviral drugs that target herpesvirus helicase primase enzymes. Herpes 10:46\u201352","journal-title":"Herpes"},{"key":"1_CR189","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJMoa1301150","volume":"370","author":"A Wald","year":"2014","unstructured":"Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L et al (2014) Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med 370:201\u2013210","journal-title":"N Engl J Med"},{"key":"1_CR190","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1001\/jama.2016.18189","volume":"316","author":"A Wald","year":"2016","unstructured":"Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang ML, Stobernack HP et al (2016) Effect of pritelivir compared with valacyclovir on genital HSV-2 shedding in patients with frequent recurrences: a randomized clinical trial. JAMA 316:2495\u20132503","journal-title":"JAMA"},{"key":"1_CR191","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jac\/dkq198","volume":"65","author":"K Chono","year":"2010","unstructured":"Chono K, Katsumata K, Kontani T, Kobayashi M, Sudo K, Yokota T, Konno K, Shimizu Y, Suzuki H (2010) ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 65:1733\u20131741","journal-title":"J Antimicrob Chemother"},{"key":"1_CR192","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1128\/AAC.00133-12","volume":"56","author":"K Katsumata","year":"2012","unstructured":"Katsumata K, Weinberg A, Chono K, Takakura S, Kontani T, Suzuki H (2012) Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor. Antimicrob Agents Chemother 56:3587\u20133591","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR193","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104829","volume":"180","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Tan L, Daikoku T, Takemoto M, Sato N, Yoshida Y (2020) Viral ribonucleotide reductase attenuates the anti-herpes activity of acyclovir in contrast to amenamevir. Antiviral Res 180:104829","journal-title":"Antiviral Res"},{"key":"1_CR194","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.antiviral.2012.12.006","volume":"97","author":"K Chono","year":"2013","unstructured":"Chono K, Katsumata K, Suzuki H, Shiraki K (2013) Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res 97:154\u2013160","journal-title":"Antiviral Res"},{"key":"1_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104754","volume":"176","author":"ZW Greeley","year":"2020","unstructured":"Greeley ZW, Giannasca NJ, Porter MJ, Margulies BJ (2020) Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus type 1. Antiviral Res 176:104754","journal-title":"Antiviral Res"},{"key":"1_CR196","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s12325-017-0642-4","volume":"34","author":"T Kusawake","year":"2017","unstructured":"Kusawake T, Keirns JJ, Kowalski D, den Adel M, Groenendaal-van de Meent D, Takada A, Ohtsu Y, Katashima M (2017) Pharmacokinetics and safety of amenamevir in healthy subjects: analysis of four randomized phase 1 studies. Adv Ther 34:2625\u20132637","journal-title":"Adv Ther"},{"key":"1_CR197","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/infdis\/jis019","volume":"205","author":"S Tyring","year":"2012","unstructured":"Tyring S, Wald A, Zadeikis N, Dhadda S, Takenouchi K, Rorig R (2012) ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis 205:1100\u20131110","journal-title":"J Infect Dis"},{"key":"1_CR198","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/1346-8138.15393","volume":"47","author":"N Shoji","year":"2020","unstructured":"Shoji N, Tanese K, Sasaki A, Horiuchi T, Utsuno Y, Fukuda K, Hoshino Y, Noda S, Minami H, Asakura W et al (2020) Pharmaceuticals and medical device agency approval summary: amenamevir for the treatment of herpes zoster. J Dermatol 47:683\u2013688","journal-title":"J Dermatol"},{"key":"1_CR199","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/1346-8138.13948","volume":"44","author":"M Kawashima","year":"2017","unstructured":"Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imafuku S, Kato T, Katsuramaki T, investigators s (2017) Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study. J Dermatol 44:1219\u20131227","journal-title":"J Dermatol"},{"key":"1_CR200","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jdermsci.2020.03.004","volume":"98","author":"Y Ueda","year":"2020","unstructured":"Ueda Y, Uta D, Tanbo S, Kawabata A, Kanayama S, Osaki M, Nozawa N, Matsumoto T, Andoh T (2020) Inhibitory effect of amenamevir on acute herpetic pain and postherpetic neuralgia in mice infected with herpes simplex virus-1. J Dermatol Sci 98:50\u201357","journal-title":"J Dermatol Sci"},{"key":"1_CR201","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00705-007-0964-7","volume":"152","author":"S Biswas","year":"2007","unstructured":"Biswas S, Jennens L, Field HJ (2007) Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch Virol 152:1489\u20131500","journal-title":"Arch Virol"},{"key":"1_CR202","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1099\/vir.0.011221-0","volume":"90","author":"S Biswas","year":"2009","unstructured":"Biswas S, Miguel RN, Sukla S, Field HJ (2009) A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J Gen Virol 90:1937\u20131942","journal-title":"J Gen Virol"},{"key":"1_CR203","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.antiviral.2008.04.005","volume":"80","author":"S Biswas","year":"2008","unstructured":"Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ (2008) Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res 80:81\u201385","journal-title":"Antiviral Res"},{"key":"1_CR204","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.antiviral.2004.02.007","volume":"64","author":"M Liuzzi","year":"2004","unstructured":"Liuzzi M, Kibler P, Bousquet C, Harji F, Bolger G, Garneau M, Lapeyre N, McCollum RS, Faucher AM, Simoneau B et al (2004) Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res 64:161\u2013170","journal-title":"Antiviral Res"},{"key":"1_CR205","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/jac\/dkn057","volume":"61","author":"S Biswas","year":"2008","unstructured":"Biswas S, Kleymann G, Swift M, Tiley LS, Lyall J, Aguirre-Hernandez J, Field HJ (2008) A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J Antimicrob Chemother 61:1044\u20131047","journal-title":"J Antimicrob Chemother"},{"key":"1_CR206","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/095632020701800102","volume":"18","author":"S Biswas","year":"2007","unstructured":"Biswas S, Swift M, Field HJ (2007) High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1. Antivir Chem Chemother 18:13\u201323","journal-title":"Antivir Chem Chemother"},{"key":"1_CR207","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/jac\/dkm182","volume":"60","author":"S Biswas","year":"2007","unstructured":"Biswas S, Smith C, Field HJ (2007) Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1. J Antimicrob Chemother 60:274\u2013279","journal-title":"J Antimicrob Chemother"},{"key":"1_CR208","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jac\/dkq135","volume":"65","author":"S Sukla","year":"2010","unstructured":"Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H, Field HJ (2010) Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor. J Antimicrob Chemother 65:1347\u20131352","journal-title":"J Antimicrob Chemother"},{"key":"1_CR209","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/infdis\/jiw129","volume":"214","author":"PT Edlefsen","year":"2016","unstructured":"Edlefsen PT, Birkmann A, Huang ML, Magaret CA, Kee JJ, Diem K, Goldner T, Timmler B, Stoelben S, Ruebsamen-Schaeff H et al (2016) No evidence of pritelivir resistance among herpes simplex virus type 2 isolates after 4 weeks of daily therapy. J Infect Dis 214:258\u2013264","journal-title":"J Infect Dis"},{"key":"1_CR210","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","volume":"84","author":"K Chono","year":"2012","unstructured":"Chono K, Katsumata K, Kontani T, Shiraki K, Suzuki H (2012) Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir). Biochem Pharmacol 84:459\u2013467","journal-title":"Biochem Pharmacol"},{"key":"1_CR211","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.2174\/0929867322666150818103624","volume":"22","author":"HL Peters","year":"2015","unstructured":"Peters HL, Ku TC, Seley-Radtke KL (2015) Flexibility as a strategy in nucleoside antiviral drug design. Curr Med Chem 22:3910\u20133921","journal-title":"Curr Med Chem"},{"key":"1_CR212","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3389\/fmicb.2020.01862","volume":"11","author":"TC Keil","year":"2020","unstructured":"Keil TC, Liu D, Lloyd M, Coombs W, Moffat JF, Visalli RJ (2020) Perspective: DNA encapsidation and capsid assembly are underexploited antiviral targets for the treatment of herpesviruses. Front Microbiol 11:1862","journal-title":"Front Microbiol"},{"key":"1_CR213","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1972","volume":"28","author":"EM Kornfeind","year":"2018","unstructured":"Kornfeind EM, Visalli RJ (2018) Human herpesvirus portal proteins: Structure, function, and antiviral prospects. Rev Med Virol 28:e1972","journal-title":"Rev Med Virol"},{"key":"1_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2019.104621","volume":"172","author":"DJ Viegas","year":"2019","unstructured":"Viegas DJ, Edwards TG, Bloom DC, Abreu PA (2019) Virtual screening identified compounds that bind to cyclin dependent kinase 2 and prevent herpes simplex virus type 1 replication and reactivation in neurons. Antiviral Res 172:104621","journal-title":"Antiviral Res"},{"key":"1_CR215","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/cmdc.201800283","volume":"13","author":"J Kankanala","year":"2018","unstructured":"Kankanala J, Wang Y, Geraghty RJ, Wang Z (2018) Hydroxypyridonecarboxylic acids as inhibitors of human cytomegalovirus pUL89 endonuclease. ChemMedChem 13:1658\u20131663","journal-title":"ChemMedChem"},{"key":"1_CR216","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201321","volume":"13","author":"BL Strang","year":"2018","unstructured":"Strang BL, Asquith CRM, Moshrif HF, Ho CM, Zuercher WJ, Al-Ali H (2018) Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data. PLoS One 13:e0201321","journal-title":"PLoS One"},{"key":"1_CR217","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1021\/acs.jmedchem.8b01827","volume":"62","author":"P Kirsch","year":"2019","unstructured":"Kirsch P, Jakob V, Oberhausen K, Stein SC, Cucarro I, Schulz TF, Empting M (2019) Fragment-based discovery of a qualified hit targeting the latency-associated nuclear antigen of the oncogenic Kaposi's sarcoma-associated herpesvirus\/human herpesvirus 8. J Med Chem 62:3924\u20133939","journal-title":"J Med Chem"},{"key":"1_CR218","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1126\/scitranslmed.aau5612","volume":"11","author":"TE Messick","year":"2019","unstructured":"Messick TE, Smith GR, Soldan SS, McDonnell ME, Deakyne JS, Malecka KA, Tolvinski L, van den Heuvel APJ, Gu BW, Cassel JA et al (2019) Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth. Sci Transl Med 11:482","journal-title":"Sci Transl Med"}],"container-title":["Advances in Experimental Medicine and Biology","Antiviral Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-16-0267-2_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T03:06:34Z","timestamp":1675566394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-16-0267-2_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9789811602665","9789811602672"],"references-count":218,"URL":"https:\/\/doi.org\/10.1007\/978-981-16-0267-2_1","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"14 July 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}